- Home
- MFA vs PHVS Comparison
MFA vs PHVS Comparison
Compare MFA & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- PHVS
- Stock Information
- Founded
- MFA 1997
- PHVS 2015
- Country
- MFA United States
- PHVS Switzerland
- Employees
- MFA N/A
- PHVS N/A
- Industry
- MFA Real Estate Investment Trusts
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- PHVS Health Care
- Exchange
- MFA Nasdaq
- PHVS Nasdaq
- Market Cap
- MFA 1.0B
- PHVS 909.5M
- IPO Year
- MFA N/A
- PHVS 2021
- Fundamental
- Price
- MFA $9.47
- PHVS $17.99
- Analyst Decision
- MFA Buy
- PHVS Buy
- Analyst Count
- MFA 6
- PHVS 6
- Target Price
- MFA $12.50
- PHVS $37.17
- AVG Volume (30 Days)
- MFA 1.2M
- PHVS 62.5K
- Earning Date
- MFA 08-07-2025
- PHVS 08-13-2025
- Dividend Yield
- MFA 15.17%
- PHVS N/A
- EPS Growth
- MFA N/A
- PHVS N/A
- EPS
- MFA 0.99
- PHVS N/A
- Revenue
- MFA $292,245,000.00
- PHVS N/A
- Revenue This Year
- MFA N/A
- PHVS N/A
- Revenue Next Year
- MFA $14.73
- PHVS N/A
- P/E Ratio
- MFA $9.58
- PHVS N/A
- Revenue Growth
- MFA 52.95
- PHVS N/A
- 52 Week Low
- MFA $7.85
- PHVS $11.51
- 52 Week High
- MFA $13.45
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- MFA 47.30
- PHVS 58.65
- Support Level
- MFA $9.36
- PHVS $16.00
- Resistance Level
- MFA $9.73
- PHVS $17.53
- Average True Range (ATR)
- MFA 0.18
- PHVS 1.14
- MACD
- MFA -0.00
- PHVS 0.01
- Stochastic Oscillator
- MFA 42.62
- PHVS 59.77
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.